By Justin Petrone

British molecular diagnostics firm Osmetech last week filed with the US Securities and Exchange Commission for an initial public offering of as much as $40 million.

Osmetech also separately reported that sales for the full-year 2009 rose 81 percent, mostly on the strength of its array-based tests, while net loss narrowed 16 percent year over year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.